Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Japan Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The Japan idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 8.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial pneumonia characterized by the thickening and scarring of lung tissue. The clinical symptoms of IPF include breathing difficulties, persistent dry cough, fatigue, loss of appetite, and swollen limbs. It is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs, which slows the rate at which the scar tissues are formed and controls the symptoms associated with the disease. Supportive therapeutic options, including pulmonary rehabilitation, palliative care, and supplemental oxygen therapy, are also provided as the effective treatment plan for IPF. 

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the IPF treatment market growth across Japan. This can be attributed to a rise in the consumption of nicotine-based products, a surge in pollution levels, and rising stress levels. Other than this, increasing health consciousness and rising awareness regarding the effective prevention and management strategies of IPF are acting as growth-inducing factors. Other factors, such as extensive research and development (R&D) activities for introducing novel therapies, and advancements in the existing healthcare infrastructure, are positively influencing the market growth across the country.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the Japan idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors
     

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others
     

Breakup by Region:

  • Kanto Region
  • Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Million
Segment Coverage Drug Class, End User, Region
Region Covered Kanto Region, Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the Japan idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan idiopathic pulmonary fibrosis treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the Japan idiopathic pulmonary fibrosis treatment market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Japan Idiopathic Pulmonary Fibrosis Treatment Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Drug Class
    6.1    MAPK Inhibitors
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Tyrosine Inhibitors
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Autotaxin Inhibitors
        6.3.1 Market Trends
        6.3.2 Market Forecast 
7    Market Breakup by End User
    7.1    Hospitals 
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Long-term Care Facilities
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Others
        7.3.1 Market Trends
        7.3.2 Market Forecast
8    Market Breakup by Region
    8.1    Kanto Region
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Kinki Region
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Central/ Chubu Region 
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Kyushu-Okinawa Region
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Tohoku Region
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Chugoku Region
        8.6.1 Market Trends
        8.6.2 Market Forecast
    8.7    Hokkaido Region
        8.7.1 Market Trends
        8.7.2 Market Forecast
    8.8    Shikoku Region
        8.8.1 Market Trends
        8.8.2 Market Forecast
9    SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10    Value Chain Analysis
11    Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12    Price Analysis
13    Policy and Regulatory Landscape
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players

List of Figures

Figure 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016-2021
Figure 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2021
Figure 7: Japan:  Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Kanto Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Kanto Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Kinki Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Kinki Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Central/ Chubu Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Central/ Chubu Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Kyushu-Okinawa Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Kyushu-Okinawa Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Tohoku Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Tohoku Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Chugoku Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Chugoku Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Hokkaido Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Hokkaido Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Shikoku Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Shikoku Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 36: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 37: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027 
Table 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
Table 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2699

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links